SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.
Profitability
This table compares SELLAS Life Sciences Group and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SELLAS Life Sciences Group | N/A | -95.20% | -75.06% |
| Dianthus Therapeutics | -7,973.33% | -38.85% | -36.42% |
Valuation & Earnings
This table compares SELLAS Life Sciences Group and Dianthus Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SELLAS Life Sciences Group | N/A | N/A | -$30.88 million | ($0.28) | -18.57 |
| Dianthus Therapeutics | $2.04 million | 1,743.92 | -$162.34 million | ($4.10) | -19.51 |
SELLAS Life Sciences Group has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
SELLAS Life Sciences Group has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for SELLAS Life Sciences Group and Dianthus Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SELLAS Life Sciences Group | 1 | 0 | 1 | 0 | 2.00 |
| Dianthus Therapeutics | 1 | 0 | 11 | 1 | 2.92 |
SELLAS Life Sciences Group currently has a consensus price target of $10.00, suggesting a potential upside of 92.31%. Dianthus Therapeutics has a consensus price target of $117.30, suggesting a potential upside of 46.63%. Given SELLAS Life Sciences Group’s higher possible upside, equities research analysts clearly believe SELLAS Life Sciences Group is more favorable than Dianthus Therapeutics.
Institutional & Insider Ownership
17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 1.4% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Dianthus Therapeutics beats SELLAS Life Sciences Group on 8 of the 14 factors compared between the two stocks.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
